Elixiron Immunotherapeutics (7871) Pre-Listing Investor Conference
Elixiron Immunotherapeutics Inc. (Stock Symbol: 7871) Pre-Emerging Stock Board Listing Investor Conference
We cordially invite you to attend our investor conference scheduled for Monday, January 5, 2026, ahead of our listing on the Emerging Stock Board. During this event, we will present our latest operational results and future outlook. We welcome your participation and guidance.
Company Overview Founded in 2017, Elixiron Immunotherapeutics specializes in developing precision immunotherapies for neuroinflammation, autoimmune diseases, and cancer. Driven by robust R&D capabilities, the company has successfully advanced two blockbuster drug candidates into clinical trials: EI-1071 (Enrupatinib), targeting Alzheimer's disease, ALS, and Parkinson's disease; and EI-001 (Indemakitug), for the treatment of vitiligo and alopecia areata.
Elixiron’s R&D achievements have garnered international recognition. In addition to winning the 2024 Taiwan BIO Awards (Outstanding Startup) and the 2025 National Innovation Award, our EI-1071 program has twice received funding from Microsoft founder Bill Gates and the Alzheimer's Association to support its Phase I and II clinical trials. To date, we have successfully concluded two patent licensing agreements, demonstrating significant commercial potential.
